Fladrafinil – Powder
From €39.80
CRL-40,941 (Fladrafinil) is a synthetic compound closely related to Modafinil and Adrafinil, known for its wakefulness-promoting and cognitive-enhancing properties. It has gained attention for its ability to improve alertness, focus, and cognitive function by influencing dopamine systems.
For a more detailed description and lab analysis, please see the sections below.
In stock
Worldwide Delivery: We ship to most international destinations with tracked services.
Fladrafinil (CRL-40,941) Powder
Scope Note: This is a scientific overview of fladrafinil as a research compound. It explains its chemistry, pharmacology, and evidence base. It is not guidance about use, and human consumption is not the subject of this article. The goal is to answer one question: why does this molecule interest neuroscientists, and how much of that interest is backed by real data?
1. The One-Paragraph
Fladrafinil (development code CRL-40,941; also fluorafinil, bisfluoroadrafinil) is a synthetic molecule from the modafinil family. It was designed in the early 1980s by Laboratoire L. Lafon, the same French company that invented modafinil, and it is essentially adrafinil with two fluorine atoms added. Those two atoms turn out to matter: fladrafinil is a prodrug that the body converts into flmodafinil (CRL-40,940), a fluorinated cousin of modafinil whose effects on dopamine and wakefulness have begun to be mapped by modern research.
The scientific promise is real but thinly documented: credible modern studies describe its active metabolite as a dopamine-targeting wake-promoter with a longer, smoother profile than modafinil in animals, and the older patent record hints at unusual behavioral properties (including reduced aggression in mice) not seen with its non-fluorinated relatives.
2. Identity Card
| Property | Detail |
|---|---|
| Chemical name | 2-[bis(4-fluorophenyl)methylsulfinyl]-N-hydroxyacetamide |
| Molecular formula | C₁₅H₁₃F₂NO₃S |
| Molecular weight | 325.3 g/mol |
| CAS number | 90212-80-9 |
| Melting point (patent) | 90–91 °C |
| Family | Benzhydrylsulfinyl acetohydroxamic acids (“-afinils”) |
| Relationship | Prodrug of flmodafinil; fluorinated analog of adrafinil |
| Approval status | Never approved as a medicine anywhere; listed as an analytical reference standard (“research/forensic use”) |
The word eugeroic (Greek for “good arousal”) describes compounds that promote alertness and vigilance through a mechanism distinct from amphetamine-like stimulants. Modafinil is the prototype; fladrafinil is its grandchild, chemically speaking.
3. Where It Sits in the “-Afinil” Family
Understanding fladrafinil is mostly an exercise in arranging four related molecules:
| Compound | Role | Relationship to Fladrafinil |
|---|---|---|
| Modafinil | The reference drug | Grandparent. Approved medicine for narcolepsy and specific sleep disorders. |
| Adrafinil | Prodrug of modafinil | “Parent” molecule: fladrafinil is adrafinil with two fluorines added. |
| Flmodafinil (CRL-40,940) | Active fluorinated analog | The compound fladrafinil is converted into. |
| Fladrafinil (CRL-40,941) | Prodrug of flmodafinil | Our subject. |
The Metabolic Cascade:
Adrafinil (prodrug) → liver enzymes → Modafinil (active drug)
So fladrafinil is best understood as “adrafinil, upgraded with fluorine.” Just as adrafinil was the historical stepping stone that led to modafinil, fladrafinil is the fluorinated stepping stone to flmodafinil.
4. Why the Chemistry Is Genuinely Promising: The Fluorine Story
The difference between fladrafinil and plain adrafinil is just two fluorine atoms — one attached to each of the two benzene (phenyl) rings, in the “para” position. In medicinal chemistry, this is a classic move, and for good reason:
4.1 Fluorine as a “Protective Shield”
The liver’s detoxification enzymes break down drugs by attacking particular weak spots — often a hydrogen atom sitting on an aromatic ring. Replacing that hydrogen with fluorine is like welding armor plate over a chink in the molecule’s armor. The carbon–fluorine bond is one of the strongest single bonds in organic chemistry, so the liver’s usual attack route is blocked.
Why it matters: The active metabolite, flmodafinil, may therefore survive longer in the body than modafinil. If a drug hangs around longer but keeps working, you might get the same effect from a smaller, less frequent amount. This is exactly the kind of advantage fluorination is designed to produce — and it is the most plausible scientific explanation for why some sources describe the fluoro-analogs as “more potent” or “longer-acting.”
4.2 Fluorine as a Tiny, Powerful Magnet
Fluorine is small (barely bigger than hydrogen) but extremely electronegative — it pulls electrons toward itself. This can:
- subtly change how strongly a molecule binds to its target protein,
- alter solubility and how easily it crosses membranes (including the blood–brain barrier),
- shift selectivity, so the molecule favors one target over related ones.
In the fladrafinil/flmodafinil pair, measured binding data (discussed below) suggest a modest improvement in affinity for the dopamine transporter — real, but not the “3–4× stronger” that some vendor marketing has claimed.
5. The Prodrug Design: A “Delayed-Release” Idea Built Into the Molecule
Fladrafinil itself is a prodrug.
The Lockbox Analogy: A prodrug is like a lockbox delivered to the liver. The molecule you start with is the box; the liver holds the key; the drug that actually does the brain work is what comes out when the box is opened.
For fladrafinil, the “key” is a metabolic step that strips off the N-hydroxy group, transforming it into flmodafinil. The 2026 human metabolism study (Section 8) confirmed this conversion directly: after fladrafinil administration, researchers found flmodafinil — plus its breakdown products — in the body, and flmodafinil’s levels peaked several hours later than the parent compound’s. That lag is the fingerprint of a prodrug.
The potential advantage: Rather than dumping all of the active molecule into circulation at once, a prodrug produces it gradually. In principle, this could mean a smoother, more sustained profile — an attractive idea for a wakefulness drug meant to last through a long day. Whether that theoretical smoothness is meaningful in practice has not been tested in controlled efficacy studies.
6. How It Is Thought to Work in the Brain
6.1 The Active Form: An “Atypical” Dopamine Reuptake Inhibitor
Flmodafinil — the molecule fladrafinil becomes — is best described as a weak, selective, atypical dopamine reuptake inhibitor (DRI). Here is the plain-language picture:
- Neurons communicate by releasing chemical messengers (neurotransmitters) into the gap between cells.
- Dopamine is one such messenger, heavily involved in wakefulness, motivation, attention, and reward.
- After dopamine is released, a “cleanup” protein — the dopamine transporter (DAT) — acts like a tiny vacuum, sucking dopamine back into the releasing cell.
- A reuptake inhibitor partially blocks that vacuum, so dopamine lingers in the gap a little longer and its signal is slightly amplified.
6.2 “Atypical” Is the Important Word
The key contrast is amphetamine:
| Feature | Classic Stimulant (Amphetamine/Cocaine) | Flmodafinil (and Modafinil) |
|---|---|---|
| Dopamine release | Forces neurons to dump large amounts | Does not cause a massive dump |
| Transporter effect | Strong blockade and efflux | Mild, partial blockade |
| Dopamine elevation (animal data) | Several hundred to >1000% of baseline | ~150–200% of baseline in the nucleus accumbens |
| Subjective profile | Euphoria, jitter, high abuse potential | Wakefulness with a milder, “cleaner” profile |
In rodents, flmodafinil’s two enantiomers raised dopamine only to about 150–200% of baseline — a gentle nudge compared with amphetamine’s fire-hose surge (Keighron et al., 2019). This is precisely why the “-afinils” are considered atypical: they promote wakefulness through a modest, selective dopamine signal rather than a stimulant flood.
Modern measurements give flmodafinil a dopamine-transporter affinity (Ki) of roughly 2,200–4,100 nM, with far weaker binding to the serotonin transporter (Ki ≈ 48,700 nM) and negligible binding to sigma-1 receptors. For perspective, that means modest — not blockbuster — DAT affinity; this is a moderate modulator, not a sledgehammer.
6.3 The Downstream Cascade
Dopamine reuptake inhibition also appears to ripple outward, indirectly influencing other wakefulness systems:
- Histamine (the brain’s natural “wake” signal; the same family targeted by antihistamines that make you sleepy)
- Orexin/hypocretin (the master regulator of the sleep–wake switch)
- Glutamate and GABA (the brain’s accelerator and brake pedals)
- Norepinephrine (arousal and focus)
Scientists still argue about which of these matters most. The honest summary: flmodafinil’s primary measurable action is a mild, selective touch on dopamine reuptake, and modafinil-family drugs are best understood as tuning the wakefulness machinery rather than blasting it.
Crucial Caveat: These target-level data come from studies of flmodafinil, not fladrafinil itself. Fladrafinil’s own binding profile has essentially never been published — but because it is converted into flmodafinil, the active metabolite’s pharmacology is the relevant one.
7. The Most Promising Experimental Findings
7.1 Longer Wakefulness, Less Sleep Disruption (Luca et al., 2018)
The most compelling modern result concerns lauflumide (NLS-4), the R-enantiomer of flmodafinil. In mice:
- Lauflumide maintained wakefulness longer than modafinil — and did so at less than half the dose.
- Neither compound produced rebound sleep afterward.
- Crucially, lauflumide disturbed normal sleep architecture less than modafinil, with a smaller increase in slow-wave (deep-sleep-range) EEG power.
Why this matters: A wakefulness drug that keeps you awake but does not corrupt the quality of the sleep you eventually get is a genuinely valuable profile. Modafinil already does this fairly well; the fluoro-analog may do it better. If these findings translated to humans (they have not been tested), it would suggest a longer-acting, cleaner wake-promoter.
7.2 A Distinctive “Atypical” Brain Signature (Zanettini et al., 2019)
Using EEG recordings in freely moving rats, researchers showed that flmodafinil’s R-enantiomer (JBG1-049) produces a brain-activity signature matching modafinil’s — and different from cocaine’s. This matters because it classifies the compound as an atypical dopamine uptake inhibitor at the systems level, reinforcing the idea that fluoro-afinils could deliver the benefits of a mild dopamine boost with lower addiction liability.
7.3 A Candidate Direction: Treating Stimulant Use Disorder (Tanda et al., 2021)
A 2021 review by NIDA-affiliated researchers made a forward-looking argument: modafinil and its structural analogs — including the bis-fluoro analogs — are candidates for treating psychostimulant (cocaine/methamphetamine) use disorder. The logic is elegant: if an “atypical” DRI can raise dopamine just enough to relieve craving and withdrawal sluggishness without producing the euphoric surge that drives addiction, it might work as a “stabilizer.” Importantly:
- The fluoro-analogs produced dopamine elevations similar in size to but longer-lasting than (R)-modafinil’s in animal studies.
- That longer duration is itself seen as a possible advantage.
This is not (yet) a clinical claim about fladrafinil — it is a hypothesis about a class of molecules, and fladrafinil sits squarely in that class as a prodrug to one of them.
7.4 The Unique Patent Hints: Reduced Aggression and “Psychotonic” Effects
Fladrafinil’s only molecule-specific pharmacology comes from the 1984 Lafon patents. In those old rodent studies (injected, at high doses), fladrafinil reportedly:
- reduced inter-group fighting between unfamiliar male mice by 58–61% (at 64–128 mg/kg, i.p.) — while adrafinil, tested side by side, produced no such effect (roughly +2% to −3%);
- increased spontaneous movement and general arousal (“psychotonic” effect);
- shortened barbiturate-induced sleep;
- sped motor recovery after experimentally induced oxygen deprivation (hypoxia);
- potentiated the behavioral effects of amphetamine and apomorphine — a signature of dopaminergic activity;
- showed a maximum non-lethal injected dose above 512 mg/kg in mice (with mortality appearing only at 1024 mg/kg) — suggestive, in crude terms, of a reasonable margin in rodents.
The anti-aggression result is intriguing because it distinguishes fladrafinil from its parent adrafinil — and hints that the fluorinated version might touch circuits beyond simple wakefulness (for example, systems involved in irritability or impulse control). The patent itself claims fladrafinil acts at roughly half the dose of adrafinil.
But the fine print matters enormously (see Section 10): these are patent data, from the 1980s, with no modern replication, no binding assays, no pharmacology beyond behavioral observation, and no published clinical development.
8. The One Modern Human Dataset: Metabolism and Elimination
In 2026, a team at the German Sport University Cologne published the first modern human data on fladrafinil (Krug et al., Drug Testing and Analysis). The study’s purpose was anti-doping methodology — how long the drug and its breakdown products remain detectable — not efficacy or safety.
- Six healthy volunteers each received a single, controlled 20 mg dose of fladrafinil or flmodafinil in a supervised research setting (with a 3-week washout between compounds).
- In urine, fladrafinil itself peaked at 2–4 hours (52–111 ng/mL) and was detectable for only about 12 hours.
- The body converted it into flmodafinil, whose peak arrived later — direct confirmation of the prodrug conversion.
- Flmodafinil’s breakdown products flmodafinil acid and flmodafinil sulfone were detected for up to two weeks in urine.
- Blood spot samples told a similar story: parent compound brief, metabolites persistent.
The take-home for science: The prodrug conversion is real and fast enough to matter, and the metabolites are remarkably long-lived. The study also documented that commercial products were mislabeled (one contained nearly double its stated concentration), which is a serious issue for any future research or analytical work with these powders.
What this study contributes to the promise: It confirms the human body handles fladrafinil the way theory predicted — conversion to flmodafinil, a delayed peak, and slow, extended elimination. That extended elimination profile is consistent with (though not proof of) the longer-action hypothesis.
What it does not do: It measured no wakefulness, no cognition, no safety, and no side effects.
9. What a “Promise” Would Look Like: Therapeutic Directions Under Discussion
Putting the threads together, here are the research directions for which fladrafinil — or the flmodafinil it becomes — looks scientifically plausible, with the appropriate honesty labels:
9.1 Wakefulness and Sleep Disorders (Promising Hypothesis)
- Basis: Modafinil is proven for narcolepsy and excessive sleepiness; flmodafinil kept mice awake longer with less sleep disruption.
- Potential scenario: A longer-acting, gentler wake-promoter for conditions like idiopathic hypersomnia or shift-related sleepiness.
- Status: Animal data only for the active metabolite; nothing specifically tested in humans.
9.2 Cognitive Dysfunction in Neuropsychiatric Disorders (Promising Hypothesis)
- Basis: Modafinil has reproducible (if modest) effects on working memory, episodic memory, and prefrontal-dependent cognition in healthy adults and across several psychiatric conditions.
- Potential scenario: As an adjunct in disorders involving impaired attention, fatigue, and motivation (e.g., depression, ADHD, schizophrenia-related cognitive deficits).
- Status: Inferred from modafinil; fladrafinil itself has zero cognition data.
9.3 Psychostimulant Use Disorder (Emerging Research Direction)
- Basis: The Tanda (2021) proposal that atypical dopamine uptake inhibitors — including the fluoro-afinils — could stabilize dopamine tone in recovery from cocaine/methamphetamine use without an addictive surge.
- Status: An active area of preclinical exploration for the class; fladrafinil has not entered this pipeline.
9.4 Asthenia/Psychasthenia — “Psychic Fatigue” (Historical Direction)
- Basis: The Lafon patents explicitly proposed fladrafinil for hypersomnia and psychasthenia — an old clinical term for persistent mental fatigue, low drive, and slowed thinking. Adrafinil was historically marketed for related problems of vigilance and ideomotor slowing in elderly patients.
- Status: Named in the 1984 patent as an intended application, with no published clinical dataset to support it.
9.5 Irritability and Impulse Control (Speculative Direction)
- Basis: The patent’s mouse aggression data, where fladrafinil — uniquely among the afinils tested — reduced fighting between unfamiliar male mice.
- Potential scenario: A wake-promoting agent with a milder “edge,” possibly relevant where stimulants worsen irritability.
- Status: Extremely preliminary; a single unreplicated animal observation.
Lab analysis — Certificates of Analysis
Every batch is independently tested by HPLC/LC-MS. Purity for current lots: ≥98%. Select a lot to view the full report.
Chemical Informations
| Technical Information | |
|---|---|
| CAS Number | 90212-80-9 |
| PubChem CID | 13316557 |
| Purity | ≥98% |
| Molecular Weight | 325.33 g/mol |
| Molecular Formula | C₁₅H₁₃F₂NO₃S |
| Melting Point | 90-91°C |
| Synonyms | 2-{[Bis(4-fluorophenyl)methyl]sulfinyl}-N-hydroxyacetamide, Fladrafinil, Fluorafinil, 2-(bis(4-fluorophenyl)methylsulfinyl)-N-hydroxyacetamide |
| SMILES Notation | C1=CC(=CC=C1C(C2=CC=C(C=C2)F)S(=O)CC(=O)NO)F |
| Application | CRL-40,941 (Fladrafinil) is an eugeroic related to and of higher potency than adrafinil, with anticonflict properties. |
| Appearance | White to pale cream powder |
| Physical State | Solid |
| Solubility | – Poorly soluble in Water – Soluble to 5 mg/mL in Ethanol – Soluble to 10 mg/mL in Isopropanol |
| Storage Conditions | Store at room temperature or cooler, in a sealed airtight container, protected from heat, light, and humidity. |
| Stability | Stable for at least two years when stored as above. |
Fladrafinil (CRL-40,941) Powder
Scope Note: This is a scientific overview of fladrafinil as a research compound. It explains its chemistry, pharmacology, and evidence base. It is not guidance about use, and human consumption is not the subject of this article. The goal is to answer one question: why does this molecule interest neuroscientists, and how much of that interest is backed by real data?
1. The One-Paragraph
Fladrafinil (development code CRL-40,941; also fluorafinil, bisfluoroadrafinil) is a synthetic molecule from the modafinil family. It was designed in the early 1980s by Laboratoire L. Lafon, the same French company that invented modafinil, and it is essentially adrafinil with two fluorine atoms added. Those two atoms turn out to matter: fladrafinil is a prodrug that the body converts into flmodafinil (CRL-40,940), a fluorinated cousin of modafinil whose effects on dopamine and wakefulness have begun to be mapped by modern research.
The scientific promise is real but thinly documented: credible modern studies describe its active metabolite as a dopamine-targeting wake-promoter with a longer, smoother profile than modafinil in animals, and the older patent record hints at unusual behavioral properties (including reduced aggression in mice) not seen with its non-fluorinated relatives.
2. Identity Card
| Property | Detail |
|---|---|
| Chemical name | 2-[bis(4-fluorophenyl)methylsulfinyl]-N-hydroxyacetamide |
| Molecular formula | C₁₅H₁₃F₂NO₃S |
| Molecular weight | 325.3 g/mol |
| CAS number | 90212-80-9 |
| Melting point (patent) | 90–91 °C |
| Family | Benzhydrylsulfinyl acetohydroxamic acids (“-afinils”) |
| Relationship | Prodrug of flmodafinil; fluorinated analog of adrafinil |
| Approval status | Never approved as a medicine anywhere; listed as an analytical reference standard (“research/forensic use”) |
The word eugeroic (Greek for “good arousal”) describes compounds that promote alertness and vigilance through a mechanism distinct from amphetamine-like stimulants. Modafinil is the prototype; fladrafinil is its grandchild, chemically speaking.
3. Where It Sits in the “-Afinil” Family
Understanding fladrafinil is mostly an exercise in arranging four related molecules:
| Compound | Role | Relationship to Fladrafinil |
|---|---|---|
| Modafinil | The reference drug | Grandparent. Approved medicine for narcolepsy and specific sleep disorders. |
| Adrafinil | Prodrug of modafinil | “Parent” molecule: fladrafinil is adrafinil with two fluorines added. |
| Flmodafinil (CRL-40,940) | Active fluorinated analog | The compound fladrafinil is converted into. |
| Fladrafinil (CRL-40,941) | Prodrug of flmodafinil | Our subject. |
The Metabolic Cascade:
Adrafinil (prodrug) → liver enzymes → Modafinil (active drug)
So fladrafinil is best understood as “adrafinil, upgraded with fluorine.” Just as adrafinil was the historical stepping stone that led to modafinil, fladrafinil is the fluorinated stepping stone to flmodafinil.
4. Why the Chemistry Is Genuinely Promising: The Fluorine Story
The difference between fladrafinil and plain adrafinil is just two fluorine atoms — one attached to each of the two benzene (phenyl) rings, in the “para” position. In medicinal chemistry, this is a classic move, and for good reason:
4.1 Fluorine as a “Protective Shield”
The liver’s detoxification enzymes break down drugs by attacking particular weak spots — often a hydrogen atom sitting on an aromatic ring. Replacing that hydrogen with fluorine is like welding armor plate over a chink in the molecule’s armor. The carbon–fluorine bond is one of the strongest single bonds in organic chemistry, so the liver’s usual attack route is blocked.
Why it matters: The active metabolite, flmodafinil, may therefore survive longer in the body than modafinil. If a drug hangs around longer but keeps working, you might get the same effect from a smaller, less frequent amount. This is exactly the kind of advantage fluorination is designed to produce — and it is the most plausible scientific explanation for why some sources describe the fluoro-analogs as “more potent” or “longer-acting.”
4.2 Fluorine as a Tiny, Powerful Magnet
Fluorine is small (barely bigger than hydrogen) but extremely electronegative — it pulls electrons toward itself. This can:
- subtly change how strongly a molecule binds to its target protein,
- alter solubility and how easily it crosses membranes (including the blood–brain barrier),
- shift selectivity, so the molecule favors one target over related ones.
In the fladrafinil/flmodafinil pair, measured binding data (discussed below) suggest a modest improvement in affinity for the dopamine transporter — real, but not the “3–4× stronger” that some vendor marketing has claimed.
5. The Prodrug Design: A “Delayed-Release” Idea Built Into the Molecule
Fladrafinil itself is a prodrug.
The Lockbox Analogy: A prodrug is like a lockbox delivered to the liver. The molecule you start with is the box; the liver holds the key; the drug that actually does the brain work is what comes out when the box is opened.
For fladrafinil, the “key” is a metabolic step that strips off the N-hydroxy group, transforming it into flmodafinil. The 2026 human metabolism study (Section 8) confirmed this conversion directly: after fladrafinil administration, researchers found flmodafinil — plus its breakdown products — in the body, and flmodafinil’s levels peaked several hours later than the parent compound’s. That lag is the fingerprint of a prodrug.
The potential advantage: Rather than dumping all of the active molecule into circulation at once, a prodrug produces it gradually. In principle, this could mean a smoother, more sustained profile — an attractive idea for a wakefulness drug meant to last through a long day. Whether that theoretical smoothness is meaningful in practice has not been tested in controlled efficacy studies.
6. How It Is Thought to Work in the Brain
6.1 The Active Form: An “Atypical” Dopamine Reuptake Inhibitor
Flmodafinil — the molecule fladrafinil becomes — is best described as a weak, selective, atypical dopamine reuptake inhibitor (DRI). Here is the plain-language picture:
- Neurons communicate by releasing chemical messengers (neurotransmitters) into the gap between cells.
- Dopamine is one such messenger, heavily involved in wakefulness, motivation, attention, and reward.
- After dopamine is released, a “cleanup” protein — the dopamine transporter (DAT) — acts like a tiny vacuum, sucking dopamine back into the releasing cell.
- A reuptake inhibitor partially blocks that vacuum, so dopamine lingers in the gap a little longer and its signal is slightly amplified.
6.2 “Atypical” Is the Important Word
The key contrast is amphetamine:
| Feature | Classic Stimulant (Amphetamine/Cocaine) | Flmodafinil (and Modafinil) |
|---|---|---|
| Dopamine release | Forces neurons to dump large amounts | Does not cause a massive dump |
| Transporter effect | Strong blockade and efflux | Mild, partial blockade |
| Dopamine elevation (animal data) | Several hundred to >1000% of baseline | ~150–200% of baseline in the nucleus accumbens |
| Subjective profile | Euphoria, jitter, high abuse potential | Wakefulness with a milder, “cleaner” profile |
In rodents, flmodafinil’s two enantiomers raised dopamine only to about 150–200% of baseline — a gentle nudge compared with amphetamine’s fire-hose surge (Keighron et al., 2019). This is precisely why the “-afinils” are considered atypical: they promote wakefulness through a modest, selective dopamine signal rather than a stimulant flood.
Modern measurements give flmodafinil a dopamine-transporter affinity (Ki) of roughly 2,200–4,100 nM, with far weaker binding to the serotonin transporter (Ki ≈ 48,700 nM) and negligible binding to sigma-1 receptors. For perspective, that means modest — not blockbuster — DAT affinity; this is a moderate modulator, not a sledgehammer.
6.3 The Downstream Cascade
Dopamine reuptake inhibition also appears to ripple outward, indirectly influencing other wakefulness systems:
- Histamine (the brain’s natural “wake” signal; the same family targeted by antihistamines that make you sleepy)
- Orexin/hypocretin (the master regulator of the sleep–wake switch)
- Glutamate and GABA (the brain’s accelerator and brake pedals)
- Norepinephrine (arousal and focus)
Scientists still argue about which of these matters most. The honest summary: flmodafinil’s primary measurable action is a mild, selective touch on dopamine reuptake, and modafinil-family drugs are best understood as tuning the wakefulness machinery rather than blasting it.
Crucial Caveat: These target-level data come from studies of flmodafinil, not fladrafinil itself. Fladrafinil’s own binding profile has essentially never been published — but because it is converted into flmodafinil, the active metabolite’s pharmacology is the relevant one.
7. The Most Promising Experimental Findings
7.1 Longer Wakefulness, Less Sleep Disruption (Luca et al., 2018)
The most compelling modern result concerns lauflumide (NLS-4), the R-enantiomer of flmodafinil. In mice:
- Lauflumide maintained wakefulness longer than modafinil — and did so at less than half the dose.
- Neither compound produced rebound sleep afterward.
- Crucially, lauflumide disturbed normal sleep architecture less than modafinil, with a smaller increase in slow-wave (deep-sleep-range) EEG power.
Why this matters: A wakefulness drug that keeps you awake but does not corrupt the quality of the sleep you eventually get is a genuinely valuable profile. Modafinil already does this fairly well; the fluoro-analog may do it better. If these findings translated to humans (they have not been tested), it would suggest a longer-acting, cleaner wake-promoter.
7.2 A Distinctive “Atypical” Brain Signature (Zanettini et al., 2019)
Using EEG recordings in freely moving rats, researchers showed that flmodafinil’s R-enantiomer (JBG1-049) produces a brain-activity signature matching modafinil’s — and different from cocaine’s. This matters because it classifies the compound as an atypical dopamine uptake inhibitor at the systems level, reinforcing the idea that fluoro-afinils could deliver the benefits of a mild dopamine boost with lower addiction liability.
7.3 A Candidate Direction: Treating Stimulant Use Disorder (Tanda et al., 2021)
A 2021 review by NIDA-affiliated researchers made a forward-looking argument: modafinil and its structural analogs — including the bis-fluoro analogs — are candidates for treating psychostimulant (cocaine/methamphetamine) use disorder. The logic is elegant: if an “atypical” DRI can raise dopamine just enough to relieve craving and withdrawal sluggishness without producing the euphoric surge that drives addiction, it might work as a “stabilizer.” Importantly:
- The fluoro-analogs produced dopamine elevations similar in size to but longer-lasting than (R)-modafinil’s in animal studies.
- That longer duration is itself seen as a possible advantage.
This is not (yet) a clinical claim about fladrafinil — it is a hypothesis about a class of molecules, and fladrafinil sits squarely in that class as a prodrug to one of them.
7.4 The Unique Patent Hints: Reduced Aggression and “Psychotonic” Effects
Fladrafinil’s only molecule-specific pharmacology comes from the 1984 Lafon patents. In those old rodent studies (injected, at high doses), fladrafinil reportedly:
- reduced inter-group fighting between unfamiliar male mice by 58–61% (at 64–128 mg/kg, i.p.) — while adrafinil, tested side by side, produced no such effect (roughly +2% to −3%);
- increased spontaneous movement and general arousal (“psychotonic” effect);
- shortened barbiturate-induced sleep;
- sped motor recovery after experimentally induced oxygen deprivation (hypoxia);
- potentiated the behavioral effects of amphetamine and apomorphine — a signature of dopaminergic activity;
- showed a maximum non-lethal injected dose above 512 mg/kg in mice (with mortality appearing only at 1024 mg/kg) — suggestive, in crude terms, of a reasonable margin in rodents.
The anti-aggression result is intriguing because it distinguishes fladrafinil from its parent adrafinil — and hints that the fluorinated version might touch circuits beyond simple wakefulness (for example, systems involved in irritability or impulse control). The patent itself claims fladrafinil acts at roughly half the dose of adrafinil.
But the fine print matters enormously (see Section 10): these are patent data, from the 1980s, with no modern replication, no binding assays, no pharmacology beyond behavioral observation, and no published clinical development.
8. The One Modern Human Dataset: Metabolism and Elimination
In 2026, a team at the German Sport University Cologne published the first modern human data on fladrafinil (Krug et al., Drug Testing and Analysis). The study’s purpose was anti-doping methodology — how long the drug and its breakdown products remain detectable — not efficacy or safety.
- Six healthy volunteers each received a single, controlled 20 mg dose of fladrafinil or flmodafinil in a supervised research setting (with a 3-week washout between compounds).
- In urine, fladrafinil itself peaked at 2–4 hours (52–111 ng/mL) and was detectable for only about 12 hours.
- The body converted it into flmodafinil, whose peak arrived later — direct confirmation of the prodrug conversion.
- Flmodafinil’s breakdown products flmodafinil acid and flmodafinil sulfone were detected for up to two weeks in urine.
- Blood spot samples told a similar story: parent compound brief, metabolites persistent.
The take-home for science: The prodrug conversion is real and fast enough to matter, and the metabolites are remarkably long-lived. The study also documented that commercial products were mislabeled (one contained nearly double its stated concentration), which is a serious issue for any future research or analytical work with these powders.
What this study contributes to the promise: It confirms the human body handles fladrafinil the way theory predicted — conversion to flmodafinil, a delayed peak, and slow, extended elimination. That extended elimination profile is consistent with (though not proof of) the longer-action hypothesis.
What it does not do: It measured no wakefulness, no cognition, no safety, and no side effects.
9. What a “Promise” Would Look Like: Therapeutic Directions Under Discussion
Putting the threads together, here are the research directions for which fladrafinil — or the flmodafinil it becomes — looks scientifically plausible, with the appropriate honesty labels:
9.1 Wakefulness and Sleep Disorders (Promising Hypothesis)
- Basis: Modafinil is proven for narcolepsy and excessive sleepiness; flmodafinil kept mice awake longer with less sleep disruption.
- Potential scenario: A longer-acting, gentler wake-promoter for conditions like idiopathic hypersomnia or shift-related sleepiness.
- Status: Animal data only for the active metabolite; nothing specifically tested in humans.
9.2 Cognitive Dysfunction in Neuropsychiatric Disorders (Promising Hypothesis)
- Basis: Modafinil has reproducible (if modest) effects on working memory, episodic memory, and prefrontal-dependent cognition in healthy adults and across several psychiatric conditions.
- Potential scenario: As an adjunct in disorders involving impaired attention, fatigue, and motivation (e.g., depression, ADHD, schizophrenia-related cognitive deficits).
- Status: Inferred from modafinil; fladrafinil itself has zero cognition data.
9.3 Psychostimulant Use Disorder (Emerging Research Direction)
- Basis: The Tanda (2021) proposal that atypical dopamine uptake inhibitors — including the fluoro-afinils — could stabilize dopamine tone in recovery from cocaine/methamphetamine use without an addictive surge.
- Status: An active area of preclinical exploration for the class; fladrafinil has not entered this pipeline.
9.4 Asthenia/Psychasthenia — “Psychic Fatigue” (Historical Direction)
- Basis: The Lafon patents explicitly proposed fladrafinil for hypersomnia and psychasthenia — an old clinical term for persistent mental fatigue, low drive, and slowed thinking. Adrafinil was historically marketed for related problems of vigilance and ideomotor slowing in elderly patients.
- Status: Named in the 1984 patent as an intended application, with no published clinical dataset to support it.
9.5 Irritability and Impulse Control (Speculative Direction)
- Basis: The patent’s mouse aggression data, where fladrafinil — uniquely among the afinils tested — reduced fighting between unfamiliar male mice.
- Potential scenario: A wake-promoting agent with a milder “edge,” possibly relevant where stimulants worsen irritability.
- Status: Extremely preliminary; a single unreplicated animal observation.
Lab analysis — Certificates of Analysis
Every batch is independently tested by HPLC/LC-MS. Purity for current lots: ≥98%. Select a lot to view the full report.
Chemical Informations
| Technical Information | |
|---|---|
| CAS Number | 90212-80-9 |
| PubChem CID | 13316557 |
| Purity | ≥98% |
| Molecular Weight | 325.33 g/mol |
| Molecular Formula | C₁₅H₁₃F₂NO₃S |
| Melting Point | 90-91°C |
| Synonyms | 2-{[Bis(4-fluorophenyl)methyl]sulfinyl}-N-hydroxyacetamide, Fladrafinil, Fluorafinil, 2-(bis(4-fluorophenyl)methylsulfinyl)-N-hydroxyacetamide |
| SMILES Notation | C1=CC(=CC=C1C(C2=CC=C(C=C2)F)S(=O)CC(=O)NO)F |
| Application | CRL-40,941 (Fladrafinil) is an eugeroic related to and of higher potency than adrafinil, with anticonflict properties. |
| Appearance | White to pale cream powder |
| Physical State | Solid |
| Solubility | – Poorly soluble in Water – Soluble to 5 mg/mL in Ethanol – Soluble to 10 mg/mL in Isopropanol |
| Storage Conditions | Store at room temperature or cooler, in a sealed airtight container, protected from heat, light, and humidity. |
| Stability | Stable for at least two years when stored as above. |
